Bendamustine: The remedy that came in from the cold

Blood

Volumn 123, Issue 7, 2014, Pages 948-950

  Lentzsch, Suzanne ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYTOGENETICS; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MONOTHERAPY; MULTIPLE MYELOMA; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES;

EID: 84897838375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-539817     Document Type: Note

References (10)

1. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib- dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123(7):985-991.
2. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 2011;48(suppl 1):S12-S23.
3. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The effi cacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica. 2005;90(9):1287-1288. (Pubitemid 41375295)
4. Pönisch W, Rozanski M, Goldschmidt H, et al East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008;143(2):191-200.
5. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119(20):4608-4613.
6. Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol. 2013;162(2):202-209.
7. Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013;139(3):499-508.
8. Rodon P, Hulin C, Pegourie B, et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly MM progressive after 1st line therapy (IFM-2009-01 trial): predictive factors of favourable outcome [abstract]. Haematologica. 2013;98(suppl 1):100. Abstract P231.
9. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160(3): 321-330.
10. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011; 155(5):632-634.